A dose-ranging study of imeglimin in Japanese type 2 diabetic subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imeglimin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Cmic; Poxel

Most Recent Events

20 Apr 2023 According to a Poxel media release, post-hoc analysis data from this study will be presented at the 66th Annual Meeting of the Japanese Diabetes Society (JDS) 2023.
22 Mar 2018 Results presented in the Poxel media release.
15 Sep 2017 Full results will be available in second quater 2017 as per results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight